Financials

v3.23.2
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 105 $ 2,937
Restricted cash 17 196
Receivables 9 36
Inventory 106
Prepaid expenses and other current assets 229 314
Discontinued operations - current assets 32 14
Current assets held for sale 106
Total current assets 498 3,603
Property and equipment, net 9 224
Other assets 48 48
Operating lease right-of-use assets, net 124 183
Noncurrent assets held for sale 133
Total assets 812 4,058
Current liabilities:    
Accounts payable 597 695
Accrued clinical trials expenses 3 5
Other accrued liabilities 676 1,483
Operating lease liability, current 128 122
Deferred grant revenue 16 196
Discontinued operations – current liabilities 190 129
Current liabilities held for sale 236
Total current liabilities 1,846 2,630
Operating lease liability, noncurrent 65
Total liabilities 1,846 2,695
Stockholders’ equity (deficit):    
Common stock, at amounts paid-in, $0.001 par value per share; 225,000,000 shares authorized, 15,016,295 shares issued and outstanding at June 30, 2023 and December 31, 2022. 15 15
Additional paid-in capital 388,473 387,609
Accumulated deficit (389,522) (386,261)
Total stockholders’ equity (deficit) (1,034) 1,363
Total liabilities and stockholders’ equity (deficit) $ 812 $ 4,058

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.23.2
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Total revenues $ 83 $ 150 $ 181 $ 341
Operating expenses:        
Research and development 442 974 1,003 2,383
General and administrative 1,229 1,618 2,463 2,939
Total operating expenses 1,671 2,592 3,466 5,322
Loss from operations (1,588) (2,442) (3,285) (4,981)
Other income (expense):        
Interest income 7 5 29 5
Other expense, net (5) (25) (5) (26)
Other income (expense), net 2 (20) 24 (21)
Net loss $ (1,586) $ (2,462) $ (3,261) $ (5,002)
Basic net loss per common share $ (0.11) $ (0.18) $ (0.22) $ (0.41)
Diluted net loss per common share $ (0.11) $ (0.18) $ (0.22) $ (0.41)
Weighted average shares used in computing basic net loss per common share 15,016 13,692 15,016 12,218
Weighted average shares used in computing diluted net loss per common share 15,016 13,692 15,016 12,218
License and Service [Member]        
Revenues:        
Total revenues $ 1 $ 3 $ 1 $ 5
Grant [Member]        
Revenues:        
Total revenues $ 82 $ 147 $ 180 $ 336

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL
v3.23.2
CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (3,261) $ (5,002)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 82 103
Stock-based milestone payment 50
Stock-based compensation 554 497
Other 2
Changes in operating assets and liabilities:    
Receivables 18 11
Inventory (176)
Prepaid expenses and other assets 76 (66)
Accounts payable (37) (363)
Deferred grant revenue (180) (130)
Other accrued liabilities (263) 343
Net cash used in operating activities (3,011) (4,731)
Cash flows from financing activities:    
Net proceeds from equity offering 4,980
Net proceeds from the exercises of common stock warrants 4
Net cash provided by financing activities 4,984
Net increase (decrease) in cash, cash equivalents and restricted cash (3,011) 253
Cash, cash equivalents and restricted cash at beginning of period 3,133 6,332
Cash, cash equivalents and restricted cash at end of period 122 6,585
Supplemental cash flow information:    
Reclassification of inventory to assets held for sale 105
Reclassification of property and equipment, net to assets held for sale 133
Reclassification of accrued liabilities to liabilities held for sale 236
Cash and cash equivalents 105 6,420
Restricted cash 17 165
Cash, cash equivalents and restricted cash shown in the condensed statements of cash flows $ 122 $ 6,585

Source

PDF HTML
10-Q Filing
ZIP XLS HTML
XBRL